The memory effect of heteropolyoxotungstate (PM-19) pretreatment on infection by herpes simplex virus at the penetration stage

被引:33
作者
Dan, K
Miyashita, K
Seto, Y
Fujita, H
Yamase, T
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Shinjuku Ku, Tokyo 160, Japan
[2] Tokyo Inst Technol, Res Lab Resources Utilizat, Midori Ku, Yokohama, Kanagawa 227, Japan
关键词
anti-HSV activity; PCR; penetration; polyoxometalate; viral genome synthesis;
D O I
10.1016/S1043661802001706
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The keggin-type heteropolyoxotungstate K-7[PTi2W10O40].6H(2)O (PM-19) is a potent polyoxometalate (PM) inhibitor of the replication of herpes simplex virus (HSV). Pretreatment of Vero cells with PM-I 9 prior to HSV-2 infection enhanced the antiviral potency of PM-19 almost 10-fold compared with treatment of the cells only after infection. The Pretreatment effect of PM-19 is called 'the memory effect'. The memory effect was reflected by inhibition of plaque formation and decrease of intracellular virus DNA quantity, and was strongest when PM-19 was present during the penetration stage of HSV-2 infection. The effect was maintained under conditions of fusion induced by polyethyleneglycol treatment. This suggests that PM-19 does not act at the fusion stage of infection. Using the infectious center assay method, it was clarified that a second round of infection was inhibited by about 30% in the presence of PM-19 at the penetration stage compared with the virus control in nontreated cells. The inhibition was enhanced to about 60% by PM-19 pretreatment prior to infection. This suggests that PM-19 pretreatment of the cells protects them against HSV-2 infection. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 28 条
[1]  
ADUMA P, 1995, MOL PHARMACOL, V47, P816
[2]  
CERNY J, 1992, MOL PHARMACOL, V42, P537
[3]   Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC (nectin-1) with different affinities [J].
Connolly, SA ;
Whitbeck, JC ;
Rux, AH ;
Krummenacher, C ;
Littel-van den Hurk, SV ;
Cohen, GH ;
Eisenberg, RJ .
VIROLOGY, 2001, 280 (01) :7-18
[4]   Quantitation of herpes simplex viral DNA in vero cells for evaluation of an antiviral agent using the polymerase chain reaction [J].
Dan, K ;
Miyashita, K ;
Seto, Y ;
Yamase, T .
JOURNAL OF VIROLOGICAL METHODS, 1998, 76 (1-2) :73-79
[5]  
DAN K, IN PRESS PHARMACOLOG
[6]  
DAN K, 1990, JPN J PHARM S, V52, P168
[7]   ANTITUMOR-ACTIVITY OF NEW ANTITUMOR SUBSTANCE, POLYOXOMOLYBDATE, AGAINST SEVERAL HUMAN CANCERS IN ATHYMIC NUDE-MICE [J].
FUJITA, H ;
FUJITA, T ;
SAKURAI, T ;
YAMASE, T ;
SETO, Y .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 168 (02) :421-426
[8]   INVITRO ANTIVIRAL ACTIVITY OF POLYOXOTUNGSTATE (PM-19) AND OTHER POLYOXOMETALATES AGAINST HERPES-SIMPLEX VIRUS [J].
FUKUMA, M ;
SETO, Y ;
YAMASE, T .
ANTIVIRAL RESEARCH, 1991, 16 (04) :327-339
[9]  
FUKUMA M, 1989, JPN J PHARM S, V49, P72
[10]   ANTI-HIV-1 ACTIVITY, TOXICITY, AND STABILITY STUDIES OF REPRESENTATIVE STRUCTURAL FAMILIES OF POLYOXOMETALATES [J].
HILL, CL ;
WEEKS, MS ;
SCHINAZI, RF .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (10) :2767-2772